Rocket Pharmaceuticals ($RCKT): cardiovascular and hematological gene therapy, first commercial launch, and runway through 2027

Summary and Evaluation

Rocket Pharmaceuticals at a Turning Point Toward Commercialization

Before going into detail, here is a table showing the current price and various valuation scenarios, defined based on the progress of key clinical and regulatory catalysts: the approval of KRESLADI, Phase 2 data for Danon, progress on ACM/BAG3, financial stability, and the potential for strategic partnerships in cardiovascular gene therapy.

Valuation Scenarios

My price scenarios for Rocket Pharmaceuticals

Company Analysis

Rocket Pharmaceuticals Inc ($RCKT)

Rocket Pharmaceuticals is a biotechnology company focused on the development of gene therapies for rare genetic diseases. Its approach is based on designing treatments with the potential for a single administration, aimed at correcting underlying genetic alterations using viral vectors that introduce functional copies of genes into the patient’s cells, thereby addressing the cause of the disease rather than merely treating symptoms.

Founded in 2015, it is an integrated biotechnology company that develops gene therapies through two main platforms: ex vivo lentiviral (LV) vectors for hematologic disorders and in vivo adeno-associated virus (AAV) vectors for genetic cardiomyopathies. This approach allows you to select the most appropriate vector for each disease and build a diversified pipeline with disease-modifying potential.

Beyond clinical development, the company has invested in its own manufacturing capabilities, with a facility of approximately 100,000 square meters in Cranbury (New Jersey) from which it produces clinical material and moves towards commercial supply.

Clinical pipeline

KRESLADI™, RP-A501, and the cardiovascular pipeline

Its leading candidate, KRESLADI™ (RP-L201; marnetegragene autotemcel), is an ex vivo lentiviral gene therapy intended to treat severe Leukocyte Adhesion Deficiency-I (LAD-I), a pediatric disease characterized by recurrent, life-threatening infections. The Biologics License Application (BLA) is under priority review, with a PDUFA date scheduled for March 28, 2026. If approved, this would mark the company's first commercial launch and could lead to the award of a pediatric priority review voucher.

Beyond KRESLADI, the main driver of value in the medium term is RP-A501, targeting Danon disease, a severe genetic cardiomyopathy associated with early-onset heart failure. In Phase 1 (data published in NEJM 2025), the treatment demonstrated sustained LAMP2 expression in cardiomyocytes, sustained reductions in left ventricular mass, and improvements in cardiac biomarkers, with all patients alive and transplant-free during the available follow-up period.

In the field of hematology, the company has strategically prioritized its resources, discontinuing the development of RP-L102 for Fanconi anemia while continuing other ongoing programs, such as the one targeting pyruvate kinase deficiency. In the U.S. and Europe alone, genetic cardiomyopathies such as Danon syndrome, PKP2-ACM, and BAG3-DCM affect more than 100,000 patients, and under typical pricing assumptions for gene therapy, the addressable market exceeds ~1,000 M USD annually at maturity.

Fundamental analysis

Valuation, Balance Sheet, and Profitability

RCKT is trading at a PER of -2.3x (TTM losses), a figure that primarily reflects its pre-commercial phase. The P/B of 1.8x stands out as particularly attractive compared to its peers and the sector, reflecting the value of its intellectual property, the GMP facility in Cranbury, and the clinical data it has generated. The P/S ratio is technically N/A, but the implied upside estimated by analysts is +92.31 TP3T on average.

Identified catalysts

Catalysts with a defined time window for $RCKT

Risks of the thesis

Real Risks I See at Rocket Pharmaceuticals

Technical Analysis

$RCKT — Technical Consolidation Amid a Context of Catalysts

Following a bearish gap and a prolonged period of consolidation throughout much of the previous year, $RCKT began a significant uptrend in early 2026, breaking through key structural resistance levels. From its recent highs (the $5.40–$5.45 range), the stock has entered a natural corrective phase, pulling back toward the $4.60–$4.70 range. This behavior is typical following aggressive breakouts, during which part of the market takes profits, testing the strength of the new support levels.

The daily chart shows a clear transition from a prolonged sideways range to a pattern of higher lows in the medium term. At current levels, the stock is testing a relevant intermediate support zone, with key support at $4.15–$4.20 and a critical level at $4.00. Defending this range will be crucial: reversal candles would suggest that strong players are absorbing supply, while a sustained break below it could send the price back to the previous consolidation range.

The RSI (14) stands at 44.71, after normalizing the overbought readings from the previous rally—a healthy «cooling off» that leaves room for a new uptrend. The MACD This confirms the current corrective phase, with the signal line crossing downward and the histogram in negative territory (−0.0637), reflecting short-term bearish momentum, which is typical before catalytic events.

Synthesis

Rocket Pharmaceuticals isn't just another biotech company in the experimental phase: it is crossing the industry's most complex threshold—moving from clinical promise to commercial reality in gene therapy. Financially, the company has a solid structure for its current stage, with a runway extending through Q2 2027 that allows it to meet key milestones without aggressive dilutions.

The real turning point is the PDUFA on March 28, 2026 For KRESLADI™ in LAD-I: this is not just a binary event; it is the validation of the entire ex vivo lentiviral platform. At the same time, RP-A501 at Danon has already demonstrated high-quality clinical data, positioning itself as the true driver of value in the medium term within the cardiovascular platform.

The risk is clear and binary—a setback in the PDUFA process could push it to $2–3—but the upside is equally well-defined ($8–12 base case, $12–18 bullish scenario). For an investor who understands the dynamics of gene therapies and the significance of regulatory milestones, Rocket represents that exact point where the market is still hesitant and where the greatest asymmetries are being created.